Desensitization Protocol for Cemiplimab-Related Infusion Reaction in Cutaneous Squamous Cell Carcinoma: A Case Report and Literature Review.
Marco BaniniViola SalvestriniAlessandra VultaggioMargherita PerlatoValentina MecheriCecilia CerbaiVieri ScottiAndrea MatucciMonica MangoniLorenzo LiviPierluigi BonomoPublished in: Current oncology (Toronto, Ont.) (2023)
Our experience highlights the need for a DD protocol in order to improve the treatment of HSRs, particularly when elicited by an immunotherapy agent, preventing treatment discontinuation and preserving its efficacy.